Greenwich Lifesciences Inc (GLSI)

$10.08 -0.73 (-6.75%)
Market Cap 144.51M
Revenue (ttm) 0.00
Net Income (ttm) -15.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 163,100
Avg Vol 43,368
Day's Range N/A - N/A
Shares Out 13.37M
Stochastic %K 43%
Beta 1.63
Analysts Strong Sell
Price Target $39.00

Company Profile

Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. Greenwich LifeSciences, Inc. was formerly known as Norwell, Inc. and changed its name to Greenwich LifeSciences, Inc. in March 2018. The company was inco...

Industry: Biotechnology
Sector: Healthcare
Phone: 832-819-3232
Address:
Building 14, 3992 Bluebonnet Dr., Stafford, United States
doc123266
doc123266 Jul. 16 at 2:13 AM
$GLSI not sure what @Gulfoil is talking about.
1 · Reply
msgbrdinfo
msgbrdinfo Jul. 15 at 10:49 PM
$GLSI 2 days ago it was over 11. Just 2 days ago. Nobody had any worries about the trial or signups. The daily RSI was overbought over 70 and the stochastic was starting to turn down. Traders sell when shares are overbought. The answer is always traders doing their thing.
1 · Reply
Gulfoil
Gulfoil Jul. 15 at 6:46 PM
$GLSI unless there is solid news bears are in control of this stock. Unfortunately……
0 · Reply
yft212
yft212 Jul. 15 at 5:44 PM
$TMC $GLSI
0 · Reply
Alwaysdiversify
Alwaysdiversify Jul. 15 at 4:27 PM
$GLSI Question for the board: Unless you are a trapped short or have inside info about pending news (such as when it will be issued or the results), who in their right mind would short this stock when considering the massive potential for the SP to soar on positive interim results for Phase III? From a risk/reward standpoint, it just seems ludicrous to short now when so close to interim results. Besides, assuming he is not restricted from buying, Snehal essentially keeps a floor on this with his consistent buys.
4 · Reply
Alwaysdiversify
Alwaysdiversify Jul. 15 at 4:04 PM
$GLSI On March 17, 2025, GLSI announces positive safety results on a Phase III trial. The stock closes down on the day. Today, $KAPA announces positive safety results on a Phase II trial, and the stock is up big on the day. Go figure.......
0 · Reply
yft212
yft212 Jul. 15 at 3:23 PM
$GLSI https://www.iborrowdesk.com/report/GLSI
0 · Reply
yft212
yft212 Jul. 15 at 2:56 PM
$GLSI Added.
0 · Reply
doc123266
doc123266 Jul. 15 at 2:35 PM
$GLSI Snehal hasn’t bought in months
1 · Reply
Grey_Squirrel
Grey_Squirrel Jul. 15 at 2:29 PM
$GLSI added another 800
0 · Reply
Latest News on GLSI
Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Apr 3, 2025, 8:00 AM EDT - 3 months ago

Greenwich LifeSciences Provides Global Update on FLAMINGO-01

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Apr 2, 2025, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Announces Positive Immune Response Data from FLAMINGO-01 Phase III Clinical Trial

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Mar 27, 2025, 6:00 AM EDT - 3 months ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to March 31, 2026

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Mar 17, 2025, 6:45 AM EDT - 4 months ago

Greenwich LifeSciences Provides Update on Open Label Safety Data from FLAMINGO-01

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Feb 10, 2025, 6:00 AM EST - 5 months ago

Greenwich LifeSciences Provides Update on Open Label HLA Data from FLAMINGO-01

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Jan 29, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Approved to Add Additional Sites to FLAMINGO-01 in Europe

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Jan 27, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Announces Activation of Flamingo-01 in Poland

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Jan 23, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Announces Additions of Harvard and Johns Hopkins to Flamingo-01

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Jan 22, 2025, 6:00 AM EST - 6 months ago

Greenwich LifeSciences Provides Update on Commercial Manufacturing

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Jan 17, 2025, 8:20 AM EST - 6 months ago

Glancy Prongay & Murray LLP Announces Investigation of Greenwich LifeSciences, Inc. (GLSI)

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Jan 14, 2025, 6:15 AM EST - 6 months ago

Greenwich LifeSciences Announces Partnership with GBG in Germany for Flamingo-01

Greenwich LifeSciences Partners with GIM in Italy

Nov 26, 2024, 6:00 AM EST - 8 months ago

Greenwich LifeSciences Partners with GIM in Italy

Greenwich LifeSciences Provides Update on Corporate Events

Nov 18, 2024, 6:00 AM EST - 8 months ago

Greenwich LifeSciences Provides Update on Corporate Events

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Aug 1, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Provides Update on Expansion of Flamingo-01 into Spain

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Jun 26, 2024, 2:05 PM EDT - 1 year ago

Greenwich LifeSciences: Halting Of Breast Cancer Recurrence With GLSI-100

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Jun 26, 2024, 7:33 AM EDT - 1 year ago

Greenwich LifeSciences Set to Join Russell 2000 Index Again

Greenwich LifeSciences Announces $2.5 Million Private Placement

Jun 14, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Announces $2.5 Million Private Placement

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Mar 13, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to June 30, 2025

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Mar 12, 2024, 6:00 AM EDT - 1 year ago

Greenwich LifeSciences Partners with GEICAM in Spain & Conducts First Site Initiation Visits in Europe

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Feb 27, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Phase III Clinical Trial Approved to Expand into Five Largest European Countries

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Feb 22, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Flamingo-01 Manufacturing & Protocol Accepted by European Regulators

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Feb 14, 2024, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Provides Update on Phase III Clinical Trial, Flamingo-01

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Nov 21, 2023, 6:00 AM EST - 1 year ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2024

Greenwich LifeSciences Provides Year End Update

Dec 29, 2022, 6:48 AM EST - 2 years ago

Greenwich LifeSciences Provides Year End Update

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Dec 1, 2022, 6:00 AM EST - 2 years ago

Greenwich LifeSciences Extends Lock-up of Directors and Officers to End of 2023

Greenwich LifeSciences: Persevering CEO And Interesting Data

Sep 6, 2022, 5:40 PM EDT - 3 years ago

Greenwich LifeSciences: Persevering CEO And Interesting Data

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Aug 11, 2022, 10:30 AM EDT - 3 years ago

Greenwich LifeSciences Announces Activation of Clinical Sites and Commencement of Phase III Clinical Trial

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Aug 3, 2022, 8:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Flamingo-01 Phase III Clinical Trial

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Jul 28, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Financing Strategy & Corporate Update

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Jul 12, 2022, 1:18 PM EDT - 3 years ago

Here's Why Greenwich Lifesciences Shares Are Popping Off Today

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Jul 12, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Announces Removal of Clinical Hold Permitting Phase III Clinical Trial to Proceed

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Jul 11, 2022, 4:15 PM EDT - 3 years ago

Greenwich LifeSciences Announces Suspension of Share Repurchase Program

Greenwich LifeSciences to Resume Stock Repurchase Program

May 23, 2022, 7:00 AM EDT - 3 years ago

Greenwich LifeSciences to Resume Stock Repurchase Program

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

May 23, 2022, 6:00 AM EDT - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial & ASCO Meeting

Greenwich LifeSciences: A First Look

May 19, 2022, 11:12 AM EDT - 3 years ago

Greenwich LifeSciences: A First Look

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Apr 21, 2022, 8:55 AM EDT - 3 years ago

Greenwich LifeSciences: Insider Buying And Buybacks Telegraph This Company's Vast Potential

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Apr 20, 2022, 6:10 AM EDT - 3 years ago

Greenwich LifeSciences to Participate in Upcoming Jefferies, Wainwright, ASCO and BIO International Conferences

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Apr 19, 2022, 6:21 AM EDT - 3 years ago

Greenwich LifeSciences Presents Phase IIb Data, Published at AACR 2022, Further Supporting the Role of GP2 in Preventing Metastatic Breast Cancer

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Mar 3, 2022, 9:19 AM EST - 3 years ago

Greenwich LifeSciences Provides Updates on Upcoming Phase III Clinical Trial, Patent Filings, & AACR Meeting

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Feb 3, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences to Present at 2022 BIO CEO & Investor Conference

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Feb 1, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences Provides Update on Upcoming Phase III Clinical Trial, FLAMINGO-01

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Jan 24, 2022, 6:00 AM EST - 3 years ago

Greenwich LifeSciences to Implement Stock Repurchase Program for up to $10 Million & to Extend Lock-up of Insiders for an Additional 1 Year

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Dec 15, 2021, 6:00 AM EST - 3 years ago

Greenwich LifeSciences CEO Participates in TD Ameritrade Interview to Discuss 2021 SABCS Poster

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

Dec 9, 2021, 1:19 PM EST - 3 years ago

Greenwich LifeSciences Reveals 5-Year Data for GP2 Immunotherapy In Breast Cancer Settings

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Dec 9, 2021, 6:29 AM EST - 3 years ago

Greenwich LifeSciences Announces Presentation of 5 Year Data for GP2 Phase IIb Clinical Trial, Revealing Potential For New T Cell Platform Technology

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Dec 8, 2021, 7:00 AM EST - 3 years ago

Greenwich LifeSciences to Participate in Multiple Interviews and Conferences

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Dec 7, 2021, 6:34 AM EST - 3 years ago

Greenwich LifeSciences Expands Role of Industry Expert Dr. F. Joseph Daugherty to Include Medical Monitor for its Upcoming Phase III Clinical Trial

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Dec 6, 2021, 7:15 AM EST - 3 years ago

Greenwich LifeSciences Announces Commencement of the First Commercial Line Filling of GP2

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Nov 18, 2021, 6:00 AM EST - 3 years ago

Greenwich LifeSciences CEO Interview to Air on Bloomberg U.S. on the RedChip Money Report

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

Nov 17, 2021, 6:00 AM EST - 3 years ago

Greenwich LifeSciences to Participate in Jefferies' 12th Annual London Healthcare Conference

doc123266
doc123266 Jul. 16 at 2:13 AM
$GLSI not sure what @Gulfoil is talking about.
1 · Reply
msgbrdinfo
msgbrdinfo Jul. 15 at 10:49 PM
$GLSI 2 days ago it was over 11. Just 2 days ago. Nobody had any worries about the trial or signups. The daily RSI was overbought over 70 and the stochastic was starting to turn down. Traders sell when shares are overbought. The answer is always traders doing their thing.
1 · Reply
Gulfoil
Gulfoil Jul. 15 at 6:46 PM
$GLSI unless there is solid news bears are in control of this stock. Unfortunately……
0 · Reply
yft212
yft212 Jul. 15 at 5:44 PM
$TMC $GLSI
0 · Reply
Alwaysdiversify
Alwaysdiversify Jul. 15 at 4:27 PM
$GLSI Question for the board: Unless you are a trapped short or have inside info about pending news (such as when it will be issued or the results), who in their right mind would short this stock when considering the massive potential for the SP to soar on positive interim results for Phase III? From a risk/reward standpoint, it just seems ludicrous to short now when so close to interim results. Besides, assuming he is not restricted from buying, Snehal essentially keeps a floor on this with his consistent buys.
4 · Reply
Alwaysdiversify
Alwaysdiversify Jul. 15 at 4:04 PM
$GLSI On March 17, 2025, GLSI announces positive safety results on a Phase III trial. The stock closes down on the day. Today, $KAPA announces positive safety results on a Phase II trial, and the stock is up big on the day. Go figure.......
0 · Reply
yft212
yft212 Jul. 15 at 3:23 PM
$GLSI https://www.iborrowdesk.com/report/GLSI
0 · Reply
yft212
yft212 Jul. 15 at 2:56 PM
$GLSI Added.
0 · Reply
doc123266
doc123266 Jul. 15 at 2:35 PM
$GLSI Snehal hasn’t bought in months
1 · Reply
Grey_Squirrel
Grey_Squirrel Jul. 15 at 2:29 PM
$GLSI added another 800
0 · Reply
OsmanGazi
OsmanGazi Jul. 15 at 1:45 PM
$GLSI 2025-07-15 09:18:56 AM EDT 20.69 8,000 -16.36 2025-07-15 07:30:23 AM EDT 20.40 8,000 -16.07 2025-07-14 12:24:49 PM EDT 20.40 55,000 -16.07 2025-07-14 11:22:49 AM EDT 20.30 55,000 -15.97 2025-07-14 09:18:42 AM EDT 20.08 55,000 -15.75 2025-07-14 08:47:42 AM EDT 16.24 55,000 -11.91 2025-07-14 08:32:13 AM EDT 16.24 6,000 -11.9 https://chartexchange.com/symbol/nasdaq-glsi/borrow-fee/ only 8k to short...keeps going downn
0 · Reply
Rolltide2020
Rolltide2020 Jul. 15 at 1:43 PM
$GLSI 🩳 playing with 🔥.
0 · Reply
Gulfoil
Gulfoil Jul. 14 at 7:48 PM
$GLSI we eyeing closing green….
0 · Reply
tedevan
tedevan Jul. 14 at 7:41 PM
$GLSI
0 · Reply
doc123266
doc123266 Jul. 14 at 7:12 PM
$GLSI my feeling is he is just referring to the companies they are using to produce the products
1 · Reply
msgbrdinfo
msgbrdinfo Jul. 14 at 6:54 PM
$GLSI In the Redchip interview, Snehal reiterated that he cannot talk about if there are partner or acquisition deals being discussed. But, when he was discussing ramping up manufacturing in case of overwhelming response, he said they are working with their "commercial partners" on strategies to increase the scale of production. Who are the commercial partners they are strategizing with regarding manufacturing?
0 · Reply
W2Cap
W2Cap Jul. 14 at 6:49 PM
$GLSI Rate drops incoming with a new fed chair + fast tracking applications - Bio is about to finally have its moment.
0 · Reply
yft212
yft212 Jul. 14 at 4:25 PM
$GLSI Added.
0 · Reply
Gulfoil
Gulfoil Jul. 14 at 4:03 PM
$GLSI nice little attempt at a bear raid…..
0 · Reply
Gulfoil
Gulfoil Jul. 14 at 3:08 PM
$GLSI XBI is particularly strong. Maybe biotech might finally be positioned for a strong rally all the way around. This should support a strong move here. Its certainly a very interesting time to see how the short position reacts if this pushes another leg up to the 12 range.
0 · Reply
Gulfoil
Gulfoil Jul. 14 at 3:06 PM
$GLSI appears to be building a nice little base before the next leg up.
0 · Reply
W2Cap
W2Cap Jul. 14 at 8:59 AM
$GLSI question is whether there's a date that this data is supposed to be out?
1 · Reply